Search for content, post, videos

Ilya Pharma selected for Springboard’s Health Innovation Hub

Evelina Vågesjö

Ilya Pharma is one of ten life science companies selected this year for Springboard Enterprises’ Health Innovation Hub: Life Science.

The company joins over 800 experienced “been there, run that” entrepreneurs who make up the Springboard Alumnae Network, it states in its press release. This year’s cohort will convene virtually over the next several months for the Health Innovation Hub Bootcamp, after which they are matched with a personal advisory team, tasked with providing a meaningful impact on the company’s next stage of growth.

Already showing promising results

Companies recruited and qualified by Springboard’s network of advisors are among the most promising companies led by some of the most talented and accomplished women entrepreneurs.

“Ilya’s novel solution is to use genetically modified lactic acid bacteria that act as mini-bioreactors at the actual treatment site to produce the human chemokine directly to the afflicted site and there instruct the local immune cells to dampen inflammation or aid in and accelerate the healing and regenerative processes.”

Ilya Pharma are breaking new ground with their ILP-technology platform. Until now, chemokines have been underexplored as therapeutic agents in general and for gastrointestinal indications and wound care due to their short half-life. Ilya’s novel solution is to use genetically modified lactic acid bacteria that act as mini-bioreactors at the actual treatment site to produce the human chemokine directly to the afflicted site and there instruct the local immune cells to dampen inflammation or aid in and accelerate the healing and regenerative processes. The company focus on development of two drug candidates in preclinical- and clinical trials and both are already showing promising results.

“We are delighted to been selected for Springboard’s Health Innovation Hub. Gene therapy and Regenerative Medicine is an exciting area, still in its infancy and so the opportunity to get additional exposure to big pharma, investors in emerging biotech therapeutics and benefit from the experience of other pioneers in in the network is welcome,” says Evelina Vågesjö, CEO, Ilya Pharma.

Photo of Evelina Vågesjö: Mikael Wallerstedt